- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Thousand Oaks Today
By the People, for the People
Stillwater Wealth Management Group Acquires Amgen Shares
Investment firm adds 7,212 shares of biotech company to portfolio
Mar. 19, 2026 at 9:38am
Got story updates? Submit your updates here. ›
Stillwater Wealth Management Group, an institutional investor, acquired a new stake in Amgen Inc. (NASDAQ:AMGN) during the third quarter. The firm purchased 7,212 shares of the medical research company's stock, valued at approximately $2,035,000. Amgen now makes up about 1.4% of Stillwater Wealth Management Group's holdings, making it the firm's 29th largest position.
Why it matters
Amgen is a major biotech company that develops and markets a range of biologic medicines. Institutional investors closely monitor Amgen's performance and ownership changes, as the company's success can impact the broader healthcare and biotech sectors.
The details
According to a recent SEC filing, Stillwater Wealth Management Group acquired the new stake in Amgen during the third quarter. The 7,212 shares purchased are valued at around $2,035,000, making Amgen the firm's 29th largest holding at approximately 1.4% of its total portfolio.
- Stillwater Wealth Management Group acquired the Amgen shares in the third quarter of the year.
The players
Stillwater Wealth Management Group
An institutional investment firm that recently acquired a new stake in Amgen Inc.
Amgen Inc.
A global biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics to address serious illnesses.
The takeaway
Amgen's stock performance and ownership changes are closely watched by the investment community, as the company's success can have broader implications for the healthcare and biotech sectors. Stillwater Wealth Management Group's new stake in Amgen signals the firm's belief in the company's long-term potential.
